AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of formula (1)(I-X)

$$R^{3} \qquad A \qquad B \qquad (II)$$

$$E = R^{2}$$

$$(R^{30})_{m} \qquad D = R^{1}$$

$$(R^{30})_{m} \qquad D = R^{1}$$

$$(R^{30})_{m} \qquad D = R^{2}$$

$$(I-X)$$

[whereinwherein

R¹ and R² are each independently, an acidic group which may be protected, -COOR^A
(wherein R^A is hydrogen or C1-8 alkyl), -CONR^BSO₂R^C (wherein R^B is hydrogen or C1-8 alkyl,

R^C is C1-8 hydrocarbon), -SO₂NR^BCOR^C (wherein R^B and R^C are as described above),

D and E are each independently, a bond or a spacer consisting of 1-8 atom(s) in the main chain,

-D-R¹ is -CO-(CH₂)₂-R¹, -CO-(CH₂)₃-R¹, -CO-(CH₂)₄-R¹ or C1-4 alkylene-R¹, E is a bond or C1-4 alkylene,

L is an oxygen atom,

W is -O-CH₂-, -O-(CH₂)₂-, -O-(CH₂)₃-, -O-(CH₂)₄-, -O-(CH₂)₅-, -CH₂-O-, -(CH₂)₂-O-, -(CH₂)₃-O-, -(CH₂)₄-O-, -O-(CH₂)₃-O-, -O-(CH₂)₄-O-, -O-(CH₂)₅-O- or C1-6 alkylene,

$$\begin{array}{c}
\frac{V \text{ is}}{R^{110}} \\
\downarrow N \\
0
\end{array},$$

$$\begin{array}{c}
R^{110} \\
\downarrow O
\end{array},$$

$$\begin{array}{c}
O \\
\downarrow O
\end{array},$$

$$\begin{array}{c}
O \\
\downarrow O
\end{array},$$

$$\begin{array}{c}
O \\
\downarrow O
\end{array},$$

(wherein R¹¹⁰ is hydrogen or C1-8 alkyl, and the arrow means that it attaches to



in the ring

ring 1 is a benzene, naphthalene or pyridine ring which may optionally be substituted by a C1-10 straight or branched alkyl, alkenyl or alkynyl group in which optional 1-2 of the carbon atom(s) may be replaced by oxygen, benzene ring, or C5-7 carbocylic ring,

ring 2 is a benzene, naphthalene, indan or pyridine ring which may optionally be substituted by a group selected from the group consisting of hydroxy, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, fluorine, chlorine, bromine, methoxy, ethoxy, propoxy, butoxy, trifluoromethyl, methylthio, phenyl and pyridyl,

R³⁰ is hydrogen, hydroxy, Cl-4 alkyl optionally substituted with 1-3 of halogen, Cl-4 alkoxy, amino, nitro or halogen,

m is 0 or an integer of 1 to 4, and

R³-is a substituent,

ring A is a cyclic group which may have further substituent(s),

ring B is a cyclic group which may have further substituent(s),

Y and Z are each independently, a carbon atom or a nitrogen atom, and

is a single bond or a double bond (provided that Y and/or Z is/are nitrogen

atom(s), the bond is a single bond)], an N-oxide thereof, thereof or a salt thereof, a solvate thereof or a prodrug thereof.

2-9. (Cancelled)

- 10. (Currently amended) The compound according to claim 1, which is selected from the group consisting of:
- (1) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (2) 4-(3-carboxypropyl)-8-({(2E)-3-[4-(4-phenylbutyl)phenyl]-2-propenoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (3) 4-[8-{[4-(4-phenylbutoxy)benzoyl]amino}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,
- (4) 4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (5) 4-(3-carboxypropyl)-8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (6) 4-(3-carboxypropyl)-8-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (7) (2S)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (8) (2R)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (9) 4-(3-carboxypropyl)-8-({4-[2-(2,3-dihydro-1H-inden-2-yl)ethoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (10) 4-(3-carboxypropyl)-8-({4-[(5-phenylpentyl)oxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (11) 4-(3-carboxypropyl)-8-({4-[(7-phenylheptyl)oxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
 - (12) 4-(3-carboxypropyl)-8-({4-[(4-methylpentyl)oxy]benzoyl}amino)-3,4-dihydro-2H-

- 1,4-benzoxazine-2-carboxylic acid,
- (13) 4-(3-carboxypropyl)-8-{[4-(4-phenoxybutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (14) 4-(3-carboxypropyl)-8-({4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (15) 4-(3-carboxypropyl)-8-({4-[4-(4-fluorophenyl)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (16) 4-(3-carboxypropyl)-8-({4-[4-(2-methylphenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (17) 4-(3-carboxypropyl)-8-({4-[4-(2-fluorophenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (18) 4-(3-carboxypropyl)-8-({4-[4-(2-chlorophenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (19) 4-(3-carboxypropyl)-8-[(4-{4-[2-(trifluoromethyl)phenoxy]butoxy}benzoyl)amino]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (20) 4-(3-carboxypropyl)-8-({4-[3-(2-methylphenoxy)propoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (21) 4-(2-({[(4-methylphenyl)sulfonyl]amino}carbonyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (22) 4-(2-{[(methylsulfonyl)amino]carbonyl}-8-{[4-(4-phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (23) 4-(2-{[(benzylsulfonyl)amino]carbonyl}-8-{[4-(4-phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (24) 4-(3-carboxypropyl)-8-{(E)-2-[4-(4-phenoxybutoxy)phenyl]vinyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (25) 4-(3-carboxypropyl)-8-{(E)-2-[4-(2,3-dihydro-1H-inden-2-ylmethoxy)phenyl]vinyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (26) 4-(3-carboxypropyl)-8-((E)-2-{4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
 - (27) 4-(3-carboxypropyl)-8-((E)-2-{4-[(5-phenoxypentyl)oxy]phenyl}vinyl)-3,4-dihydro-

- 2H-1,4-benzoxazine-2-carboxylic acid,
- (28) 4-(3-carboxypropyl)-8-((E)-2-{4-[4-(4-methoxyphenoxy)butoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (29) 4-(3-carboxypropyl)-8-((E)-2-{4-[3-(4-fluorophenoxy)propoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (30) 4-(3-carboxypropyl)-8-{(E)-2-[4-(3-phenoxypropoxy)phenyl]vinyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (31) 4-(3-carboxypropyl)-8-((E)-2-{4-[3-(2-chlorophenoxy)propoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (32) 4-(3-carboxypropyl)-8-{2-[4-(4-phenoxybutoxy)phenyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (33) 4-[8-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,
- (34) 4-[8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,
- (35) 4-(2-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (36) 4-(2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (37) 4-oxo-4-(8-((4-(4-phenylbutoxy)benzoyl)amino)-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid, and
- (38) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzyl)oxy)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid.
- 11. (Currently amended) A pharmaceutical composition comprising the compound of formula (I)(I-X), an N-oxide thereof, thereof or a salt thereof, a solvate thereof or a prodrug-thereof according to claim 1, and a pharmaceutically acceptable agent.

12-22. (Cancelled)